

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review	11
4. Data for the <i>Monographs</i>	12
5. Meeting participants	12
6. Working procedures.....	13
B. SCIENTIFIC REVIEW AND EVALUATION	14
1. Exposure data.....	15
2. Studies of cancer in humans.....	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary	26
6. Evaluation and rationale.....	27
References.....	31
GENERAL REMARKS	33
DDT	37
1. Exposure Data.....	37
1.1. Identification of the agent	37
1.2. Production and use.....	38
1.3. Measurement and analysis.....	43
1.4. Occurrence and exposure.....	43
1.5. Regulation.....	74

2. Cancer in Humans	76
2.1 Cohort studies	76
2.2 Case-control studies	107
3. Cancer in Experimental Animals	158
3.1 Mouse	158
3.2 Rat	173
3.3 Hamster	176
3.4 Monkey	177
3.5 Carcinogenicity of metabolites of DDT	177
4. Mechanistic and Other Relevant Data	179
4.1 Toxicokinetic data	179
4.2 Mechanisms of carcinogenesis	184
4.3 Data relevant to comparisons across agents and end-points	215
4.4 Cancer susceptibility data	220
4.5 Other adverse effects	227
5. Summary of Data Reported	228
5.1 Exposure data	228
5.2 Human carcinogenicity data	229
5.3 Animal carcinogenicity data	230
5.4 Mechanistic and other relevant data	231
6. Evaluation	233
6.1 Cancer in humans	233
6.2 Cancer in experimental animals	233
6.3 Overall evaluation	233
6.4 Rationale	233
References	233
LINDANE	267
1. Exposure Data	267
1.1 Identification of the agent	267
1.2 Production and use	268
1.3 Measurement and analysis	269
1.4 Occurrence and exposure	270
1.5 Regulation	289
2. Cancer in Humans	290
2.1 Cohort studies	290
2.2 Case-control studies nested within cohorts	297
2.3 Case-control studies	299
2.4 Meta-analysis	312
3. Cancer in Experimental Animals	312
3.1 Mouse	312
3.2 Rat	320
4. Mechanistic and Other Relevant Data	321
4.1 Toxicokinetics	321
4.2 Mechanisms of carcinogenesis	324
4.3 Data relevant to comparisons across agents and end-points	341

4.4	Cancer susceptibility data	349
4.5	Other adverse effects	349
5.	Summary of data reported	353
5.1	Exposure data	353
5.2	Human carcinogenicity data	354
5.3	Animal carcinogenicity data	354
5.4	Mechanistic and other relevant data	355
6.	Evaluation	356
6.1	Cancer in humans	356
6.2	Cancer in experimental animals	356
6.3	Overall evaluation	356
	References	356
2,4-DICHLOROPHENOXYACETIC ACID		373
1.	Exposure Data	373
1.1	Identification of the agent	373
1.2	Production and use	374
1.3	Measurement and analysis	376
1.4	Occurrence and exposure	377
1.5	Regulation	399
2.	Cancer in humans	401
2.1	Cohort studies	401
2.2	Case-control studies	407
2.3	Meta-analyses	422
3.	Cancer in Experimental Animals	427
3.1	Mouse	427
3.2	Rat	436
3.3	Dog	436
4.	Mechanistic and Other Relevant Data	439
4.1	Toxicokinetics	439
4.2	Mechanisms of carcinogenesis	442
4.3	Data relevant to comparisons across agents and end-points	466
4.4	Cancer susceptibility data	472
4.5	Other adverse effects	472
5.	Summary of data reported	477
5.1	Exposure data	477
5.2	Human carcinogenicity data	477
5.3	Animal carcinogenicity data	478
5.4	Mechanistic and other relevant data	479
6.	Evaluation	480
6.1	Cancer in humans	480
6.2	Cancer in experimental animals	480
6.3	Overall evaluation	480
	References	480
LIST OF ABBREVIATIONS		499

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

